Background

Minicircles are optimized DNA-molecules for non-viral gene transfer applications. They are derived from conventional plasmid-DNA by the removal of sequences which are known to be a safety risk and to reduce the overall efficiency in clinical applications - the bacterial backbone sequences. The resulting minicircle-DNA constitutes a supercoiled, minimal expression cassette with an optimised safety and efficiency profile. Among non-viral gene transfer technologies, minicircle-DNA (mc-DNA) is regarded most promising and superior to conventional plasmid-DNA.

Many studies are ongoing or have been conducted demonstrating the advantages of these DNA-molecules in specific medical applications like for example in the field of angiogenesis, lung treatment, rheumatoid arthritis or in the treatment for myocardial infarction just to mention a few. Furthermore, the minicircle-DNA technology has already arrived in the field of CRISPR-Cas9 based gene editing, it is used as vector for RNA interference since years and has shown advantages in gene transfer applications using transposons like sleeping beauty.

Although the basic principles of minicircle production are known since decades, large scale manufacturing is still not a straight forward process. The RBPS-Technology platform has been developed to provide customers with processes needed for industrial large scale manufacturing:
  • high efficient in vivo site specific recombination process
  • in vivo restriction and degradation of unwanted bacterial backbone sequences
  • novel chromatographic approaches, including affinity based strategies based on high performance monolithic chromatography